Dexmedetomidine is a new alpha 2-adrenoceptor agonist approved for use as a sedative and analgesic in intensive care unit (ICU). Dexmedetomidine is seven to eight times more specific to the alpha-2 receptor than the partial agonist clonidine. In addition to its sedative properties, dexmedetomidine has opioidsparing, anxiolytic, sympatholytic, and respiratory-preserving properties and provides superior hemodynamic stability compared with many sedative agents now in use [1] . Dexmedetomidine is widely used for sedation in the ICU because of its beneficial effects. A previous study showed that dexmedetomidine is associated with a shortened time to extubation and reduced prevalence of delirium in critically ill patients receiving mechanical ventilation [2, 3] . A recent study reported that dexmedetomidine decreases the duration of mechanical ventilation and also enhances the rate of resolution of delirium in critically ill patients with agitated delirium [4] .
elderly patients receiving orthopedic surgery reduces postoperative agitation compared to propofol [8] . The favorable properties of dexmedetomidine, such as minimal respiratory depression, may provide protection against adverse respiratory events during anesthesia for awake craniotomy or awake intubation [9, 10] .
Many studies have demonstrated that dexmedetomidine has organ-protective effects in various anesthetic conditions. Previous studies have reported that the use of alpha 2-adrenergic agonists can reduce mortality and myocardial infarction in patients undergoing vascular surgery, and also provides a cardioprotective effect during cardiac surgery [11] . Dexmedetomidine preserves cerebral blood flow (CBF) and cerebral metabolic rate (CMR) coupling by dose-dependently reducing CBF and CMR in healthy humans [12] . Growing evidence suggests that dexmedetomidine confers neuroprotective effects in various experimental models, including hypoxia-induced ischemia, subarachnoid hemorrhage, and ischemia/reperfusion injury [13] [14] [15] . A recent clinical trial showed that continuous infusion of dexmedetomidine during cardiopulmonary bypass surgery decreases the incidence and severity of acute kidney injury [16] .
Although the various beneficial properties of dexmedetomidine have expanded its clinical use in many areas, serious side effects, such as cardiac arrest, have been reported in several studies [17, 18] . These reports suggest that dexmedetomidine should be used with caution in patients with certain conditions in which sympathetic function is suppressed or parasympathetic function is enhanced. Fujita et al. [19] reported that plasma dexmedetomidine concentration is correlated with the infusion dose in critically ill adult patients, but not in children < 2 years old admitted to the pediatric ICU [20] . These reports emphasize the need for close monitoring, individualized treatment, and dose adjustment to achieve the desired clinical response when administering dexmedetomidine. In conclusion, dexmedetomidine is a new alpha 2-adrenoceptor agonist with promising sedative and analgesic properties. The unique properties of dexmedetomidine, including anxiolytic and opioid-sparing properties and minimal respiratory depression, make it a very attractive drug in the fields of intensive care and anesthesia.
